Eli Lilly, though a late entrant, has aggressively gained share via tirzepatide (Mounjaro, Zepbound), which demonstrated superior weight-loss outcomes in head-to-head trials
What weight loss strategies have been used in the past, and to what extent did they work
Between them, they hit both fat volume and distribution, enhancing body composition more than either on its own
Q -values were calculated using the Benjamin-Hochberg procedure [21]
With this acquisition, Roche aimed to strengthen its metabolic disease franchise by gaining access to Carmots advanced portfolio, particularly a phase-2-ready dual GLP-1/GIP receptor agonist, thereby enhancing its competitive position in both obesity and diabetes markets
in Pharmaceutical Sciences from Texas Tech University Health Sciences Center